Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis
Language English Country Netherlands Media print-electronic
Document type Comparative Study, Journal Article
PubMed
29096828
DOI
10.1016/j.atherosclerosissup.2017.05.037
PII: S1567-5688(17)30079-X
Knihovny.cz E-resources
- Keywords
- Apheresis, Familial hypercholesterolaemia, miRNA,
- MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Circulating MicroRNA blood genetics MeSH
- Adult MeSH
- Phenotype MeSH
- Genetic Predisposition to Disease MeSH
- Heterozygote MeSH
- Homozygote MeSH
- Hyperlipoproteinemia Type II blood diagnosis genetics therapy MeSH
- Cholesterol, LDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoprotein(a) blood MeSH
- Aged MeSH
- Blood Component Removal adverse effects methods MeSH
- Transcriptome MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- Biomarkers MeSH
- Circulating MicroRNA MeSH
- Cholesterol, LDL MeSH
- Lipoprotein(a) MeSH
BACKGROUND: LDL/Lp(a) apheresis therapy is a well-established method of aggressively lowering LDL and Lp(a). Recently, miRNAs have been discussed as markers of vascular status including atherosclerosis. MiRNAs inhibit post-transcriptional processes through RNA duplex formation resulting in gene silencing or regulation of gene expression. MATERIALS AND METHODS: We measured a profile of 175 plasma-circulating miRNAs using pre-defined Serum/Plasma Focus Human microRNA PCR Panels in pooled samples of 11 subjects with familial hypercholesterolaemia under long-term apheresis treatment. Subsequently we analysed expressions of ten pre-selected miRNAs potentially involved in lipid homeostasis in the same group of subjects. We compared plasma-circulating miRNA levels isolated from peripheral blood collected immediately before and after apheresis. RESULTS: The greatest differences in plasma levels were found in miR-451a, miR-16, miR-19a/b, miR-223 and miR-185. In subsequent individual miRNA assay we detected a significant increase in miR-33b levels after apheresis (P < 0.05). Additionally, correlations between plasma lipids and miR-33a (P < 0.04) and miR-122 (P < 0.01) have been determined. Moreover, miR-122 levels in LDLR homozygotes were higher compared to heterozygotes after, but not before, apheresis treatment (P < 0.04). CONCLUSIONS: LDL/Lp(a) apheresis has an impact on miRNAs associated with lipid homeostasis and vascular status.
References provided by Crossref.org
Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia
An Integrative Study of Aortic mRNA/miRNA Longitudinal Changes in Long-Term LVAD Support
